Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

Videos

Anne Katz, PhD, RN
Videos
Discussing Sexual Side Effects Caused by Cancer Care
10/17/2022
Anne Katz, PhD, RN, shares her insights on talking to patients about the sexual side effects they experience during and after undergoing cancer treatments.
Anne Katz, PhD, RN, shares her insights on talking to patients about the sexual side effects they experience during and after undergoing cancer treatments.
Anne Katz, PhD, RN, shares her...
10/17/2022
Oncology
Mitesh Borad, MD, Mayo Clinic Cancer Center
Videos
Derazantinib Demonstrates Efficacy, Tolerability for Intrahepatic Cholangiocarcinoma With FGFR2 Aberrations
10/17/2022
Mitesh Borad, MD, reviews results from a pivotal phase 2 trial investigating derazantinib in chemotherapy-exposed patients with intrahepatic cholangiocarcinoma and FGFR2 fusions, mutations, or amplifications.
Mitesh Borad, MD, reviews results from a pivotal phase 2 trial investigating derazantinib in chemotherapy-exposed patients with intrahepatic cholangiocarcinoma and FGFR2 fusions, mutations, or amplifications.
Mitesh Borad, MD, reviews...
10/17/2022
Oncology
Benjamin Miron, MD, Fox Chase Cancer Center
Videos
Immune Checkpoint Inhibitors Following Platinum Chemotherapy Regimens in Urothelial Carcinoma
10/17/2022
Benjamin Miron, MD, discusses a study comparing survival on single-agent immune checkpoint inhibitors in the second-line treatment setting, following either cisplatin or carboplatin, in patients with urothelial carcinoma.
Benjamin Miron, MD, discusses a study comparing survival on single-agent immune checkpoint inhibitors in the second-line treatment setting, following either cisplatin or carboplatin, in patients with urothelial carcinoma.
Benjamin Miron, MD, discusses a...
10/17/2022
Oncology

Advertisement

Raj Veluswamy, MD, Icahn School of Medicine, New York
Videos
NTRK: Front-Line and Second-Line Treatment Options for Patients With NSCLC
10/15/2022
Rajwanth Veluswamy, MD, provides an overview of his presentation at Great Debates and Updates in Lung Cancer covering front-line and second-line treatment options for patients with NSCLC and NTRK fusions.
Rajwanth Veluswamy, MD, provides an overview of his presentation at Great Debates and Updates in Lung Cancer covering front-line and second-line treatment options for patients with NSCLC and NTRK fusions.
Rajwanth Veluswamy, MD, provides...
10/15/2022
Oncology
Kristin Higgins, MD, Winship Cancer Institute, GA
Videos
SRS and Other Local Ablative Strategies in Patients With NSCLC and Oligometastases
10/15/2022
Dr Kristin Higgins provides an overview of her presentation at Great Debates and Updates in Lung Cancer covering ablative radiation & other local modalities in systemically treated patients with NSCLC and oligometastases.
Dr Kristin Higgins provides an overview of her presentation at Great Debates and Updates in Lung Cancer covering ablative radiation & other local modalities in systemically treated patients with NSCLC and oligometastases.
Dr Kristin Higgins provides an...
10/15/2022
Oncology
Nasser Altorki, MD, Weill Cornell Medical College
Videos
Adjuvant Checkpoint Inhibitors in Resectable NSCLC
10/15/2022
Dr Nasser Altorki reviews his presentation on adjuvant checkpoint inhibitors for patients with resectable non-small cell lung cancer, from the 2022 Great Debates and Updates in Lung Cancer meeting in New York.
Dr Nasser Altorki reviews his presentation on adjuvant checkpoint inhibitors for patients with resectable non-small cell lung cancer, from the 2022 Great Debates and Updates in Lung Cancer meeting in New York.
Dr Nasser Altorki reviews his...
10/15/2022
Oncology

Advertisement

Srdan Verstovsek, MD, University of Texas MD Anderson Cancer Center
Videos
FDA Approves Pemigatinib for Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement
10/14/2022
Srdan Verstovsek, MD, discusses the study that led to the recent FDA approval of pemigatinib for patients with relapsed or refractory myeloid/lymphoid neoplasms and an FGFR1 rearrangement.
Srdan Verstovsek, MD, discusses the study that led to the recent FDA approval of pemigatinib for patients with relapsed or refractory myeloid/lymphoid neoplasms and an FGFR1 rearrangement.
Srdan Verstovsek, MD, discusses...
10/14/2022
Oncology

Advertisement

Janos L Tanyi, MD
Videos
Pafolacianine to Detect Folate Receptor-Positive Ovarian Cancer
10/12/2022
Janos Tanyi, MD, shares results and insights from the phase 3 to confirm the safety and efficacy of pafolacianine for the detection of folate receptor-positive ovarian cancer.
Janos Tanyi, MD, shares results and insights from the phase 3 to confirm the safety and efficacy of pafolacianine for the detection of folate receptor-positive ovarian cancer.
Janos Tanyi, MD, shares results...
10/12/2022
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Recent News

News
Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation
08/08/2024
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study...
08/08/2024
Oncology
FDA Approval
FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma
08/08/2024
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug...
08/08/2024
Oncology
News
Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer
08/07/2024
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the...
08/07/2024
Oncology
News
Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL
08/07/2024
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that...
08/07/2024
Oncology
News
Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer
08/07/2024
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study...
08/07/2024
Oncology
FDA Approval
FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma
08/06/2024
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO...
08/06/2024
Oncology
FDA Approval
FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma
08/02/2024
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food...
08/02/2024
Oncology
FDA Approval
FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer
08/01/2024
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab...
08/01/2024
Oncology
News
Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML
08/01/2024
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of...
08/01/2024
Oncology
News
Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
08/01/2024
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the...
08/01/2024
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use